Featured Research

from universities, journals, and other organizations

No More Seizures? New Drug Holds Promise For Epilepsy Patients

Date:
February 6, 2007
Source:
American Academy of Neurology
Summary:
People with newly diagnosed epilepsy experienced few, if any, seizures while taking the drug levetiracetam as a single therapy, giving hope to epilepsy patients who don't respond to or can't tolerate existing treatments, according to a study published in the Feb. 6, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.

People with newly diagnosed epilepsy experienced few, if any, seizures while taking the drug levetiracetam as a single therapy, giving hope to epilepsy patients who don't respond to or can't tolerate existing treatments, according to a study published in the February 6, 2007 issue of Neurology, the scientific journal of the American Academy of Neurology.

Related Articles


For the multi-center, double-blind study, researchers assigned nearly 600 adults who had at least two seizures in the previous year to the drug levetiracetam or to controlled-release carbamazepine, a common epilepsy treatment. While levetiracetam is currently used as an add-on therapy by epilepsy patients, this is the first time its effectiveness as a single therapy has been tested through a clinical trial that provided class 1 evidence of efficacy as defined by the International League Against Epilepsy.

The study found 73 percent of people taking levetiracetam and 72.8 percent of people receiving controlled-release carbamazepine remained seizure free for at least six months.

"Both drugs produced equivalent seizure freedom rates in newly diagnosed epilepsy. Levetiracetam helps fill a need for safe and well-tolerated, easy-to-use epilepsy drugs, particularly because more than 30 percent of patients do not achieve seizure control with existing treatments," said study author Martin Brodie, MD, with the Western Infirmary Epilepsy Unit in Glasgow, Scotland.

Of those remaining seizure free for six months, the study also found 80.1 percent of those taking levetiracetam and 85.4 percent of those taking carbamazepine did so at the lowest dose level.

"This trial confirms previous uncontrolled observations that most people with epilepsy will respond to their first epilepsy drug at low dosage," said Brodie.

Researchers say 14.4 percent of people taking levetiracetam withdrew from the study because of side effects such as drowsiness or dizziness, while 19.2 percent of people taking carbamazepine withdrew from the study with rash being the most common side effect.

The study was supported by UCB Pharma.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "No More Seizures? New Drug Holds Promise For Epilepsy Patients." ScienceDaily. ScienceDaily, 6 February 2007. <www.sciencedaily.com/releases/2007/02/070206095919.htm>.
American Academy of Neurology. (2007, February 6). No More Seizures? New Drug Holds Promise For Epilepsy Patients. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2007/02/070206095919.htm
American Academy of Neurology. "No More Seizures? New Drug Holds Promise For Epilepsy Patients." ScienceDaily. www.sciencedaily.com/releases/2007/02/070206095919.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins